Rocket Pharmaceuticals (RCKT) Misses Q4 EPS by 15c
Tweet
Share
E-mailGet Alerts RCKT Hot Sheet
Join SI Premium – FREE
Rocket Pharmaceuticals (NASDAQ: RCKT) reported Q4 EPS of ($0.92), $0.15 worse than the analyst estimate of ($0.77).
For earnings history and earnings-related data on Rocket Pharmaceuticals (RCKT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- CVG to join Russell 2000 and Russell 3000 indexes June 26
- Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
